Remove Antibody Remove Bioavailability Remove Drug Delivery Remove Protein
article thumbnail

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83
article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. When using a CPP as a delivery system, it must first be conjugated to its cargo molecule and internalised through endocytosis.